S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
NASDAQ:PTGX

Protagonist Therapeutics (PTGX) Stock Forecast, Price & News

$28.20
+0.71 (+2.58%)
(As of 06/2/2023 ET)
Compare
Today's Range
$27.27
$28.26
50-Day Range
$18.02
$28.20
52-Week Range
$6.91
$28.26
Volume
725,409 shs
Average Volume
918,301 shs
Market Capitalization
$1.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.67

Protagonist Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
26.5% Upside
$35.67 Price Target
Short Interest
Healthy
6.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of Protagonist Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.34) to ($2.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

376th out of 983 stocks

Pharmaceutical Preparations Industry

179th out of 486 stocks


PTGX stock logo

About Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTGX Stock News Headlines

The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
4 Analysts Have This to Say About Protagonist Therapeutics
Protagonist Therapeutics (PTGX) Receives a Buy from JMP Securities
Protagonist Therapeutics (NASDAQ:PTGX) Trading 4.3% Higher
Protagonist Therapeutics (NASDAQ:PTGX) Trading 3.9% Higher
Why Protagonist Therapeutics Shares Are Nosediving
See More Headlines

PTGX Price History

PTGX Company Calendar

Last Earnings
3/15/2023
Today
6/04/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTGX
Fax
N/A
Employees
118
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.67
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+26.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-127,390,000.00
Pretax Margin
-16,319.91%

Debt

Sales & Book Value

Annual Sales
$859,000.00
Book Value
$3.78 per share

Miscellaneous

Free Float
54,388,000
Market Cap
$1.61 billion
Optionable
Not Optionable
Beta
1.97

Key Executives

  • Dinesh V. Patel
    President, Chief Executive Officer & Director
  • Asif Ali
    Chief Financial Officer & Executive Vice President
  • Mohammad Masjedizadeh
    Chief Technical Officer & Executive VP
  • Arturo Molina
    Chief Medical Officer
  • Matthew M. Gosling
    Executive Vice President & General Counsel













PTGX Stock - Frequently Asked Questions

Should I buy or sell Protagonist Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings
or view top-rated stocks.

What is Protagonist Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 12-month target prices for Protagonist Therapeutics' shares. Their PTGX share price forecasts range from $28.00 to $41.00. On average, they anticipate the company's stock price to reach $35.67 in the next year. This suggests a possible upside of 26.5% from the stock's current price.
View analysts price targets for PTGX
or view top-rated stocks among Wall Street analysts.

How have PTGX shares performed in 2023?

Protagonist Therapeutics' stock was trading at $10.91 at the start of the year. Since then, PTGX stock has increased by 158.5% and is now trading at $28.20.
View the best growth stocks for 2023 here
.

When is Protagonist Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PTGX earnings forecast
.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.02.

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (8.04%), BlackRock Inc. (7.69%), BVF Inc. IL (6.60%), Farallon Capital Management LLC (4.57%), State Street Corp (4.22%) and Dimensional Fund Advisors LP (2.20%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel and Sarah B Noonberg.
View institutional ownership trends
.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $28.20.

How much money does Protagonist Therapeutics make?

Protagonist Therapeutics (NASDAQ:PTGX) has a market capitalization of $1.61 billion and generates $859,000.00 in revenue each year. The company earns $-127,390,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis.

How many employees does Protagonist Therapeutics have?

The company employs 118 workers across the globe.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The official website for the company is www.protagonist-inc.com. The company can be reached via phone at (510) 474-0170 or via email at bkorb@soleburytrout.com.

This page (NASDAQ:PTGX) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -